Last updated: February 20, 2026
Aricept (donepezil) is a widely prescribed medication for Alzheimer's disease. Its production is dominated by several key suppliers, primarily comprising original equipment manufacturers (OEMs) and contract manufacturing organizations (CMOs). Market concentration remains high, with the original patent holder and a limited number of secondary suppliers.
Major Suppliers
Original Manufacturer
Eisai developed and markets Aricept, holding the original patent until patent expiration in most regions. Their manufacturing facilities are located primarily in Japan, with licensed production worldwide.
Contract Manufacturers and Approved Suppliers
Post-patent expiration, several generic manufacturers have entered the market, producing donepezil formulations under licensing agreements or through independent generic drug approvals in various jurisdictions.
| Company |
Country of Operation |
Production Capacity (Estimate) |
Notes |
| Teva Pharmaceutical Industries |
Israel |
Large-scale |
Among the first generics, with extensive global reach |
| Mylan (now part of Viatris) |
US/Panama |
Large-scale |
Key supplier in North America and Europe |
| Novartis (Sandoz division) |
Switzerland |
Moderate |
Focus on Europe and North America |
| Torrent Pharmaceuticals |
India |
Growing |
Expanding presence in Asia and emerging markets |
| Cipla |
India |
Growing |
Offers cost-effective generic options |
| Sun Pharmaceuticals |
India |
Growing |
Supplies numerous markets with certifiable quality standards |
Additional Suppliers
- Lupin Ltd. (India): Produces generic donepezil intended for various markets.
- Dr. Reddy's Laboratories (India): Provides generic options primarily in Asia and Latin America.
- Aurobindo Pharma: Active production of donepezil generics, with high-volume outputs.
Regional Variations
- United States: Dominated by generic producers like Teva, Mylan, and Novartis.
- Europe: Market includes Novartis/Sandoz and other European-approved generic firms.
- Asia: Indian companies such as Sun, Cipla, and Aurobindo are principal suppliers.
Regulatory and Certification Status
- Suppliers must hold approvals from regulatory agencies, such as the FDA (U.S.), EMA (Europe), or local health authorities.
- Good Manufacturing Practice (GMP) certifications are mandatory for legal distribution.
Supply Chain Factors
- Patents: Expired in most regions (e.g., U.S. in 2015), enabling generics.
- Manufacturing capacity: Limited by plant accreditation, raw material availability, and regulatory compliance.
- Pricing and sourcing: Competitive bidding influences procurement decisions, especially for large healthcare providers.
Summary
Major suppliers for Aricept include Eisai (original) and a broad base of global generic manufacturers, predominantly in India, Israel, and Europe. Market competition shifted significantly after patent expiry, leading to increased availability but price pressures.
Key Takeaways
- Eisai remains the sole original manufacturer.
- The generic market is highly competitive, with Teva, Mylan, and Indian companies as primary suppliers.
- Regional licensing and approvals vary, influencing availability and pricing.
- Regulatory compliance and GMP standards underpin supplier legitimacy.
- Supply dynamics are driven by patent status, manufacturing capacity, and procurement policies.
FAQs
1. Who is the original patent holder for Aricept?
Eisai Co., Ltd. holds the original patent rights for Aricept until patent expiration in most regions, around 2015.
2. Which companies supply generic donepezil?
Teva, Mylan, Sun Pharmaceuticals, Cipla, and Aurobindo Pharma supply generic donepezil in multiple markets.
3. Are there any restrictions on sourcing donepezil generics?
Yes. Regulatory approvals (FDA, EMA, local agencies) are required. Manufacturing must meet GMP standards.
4. How do regional patent laws affect supply?
Patent expirations enable generic production. In regions with extended patents or legal disputes, generic availability may be delayed.
5. Are supply shortages common for Aricept?
Historically, shortages have been rare but can occur during manufacturing disruptions, raw material shortages, or supply chain disruptions.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases
[2] European Medicines Agency. (2022). Community Register of Medicines. Retrieved from https://www.ema.europa.eu/en/medicines
[3] GlobalData. (2022). Pharmaceutical Market Intelligence for Donepezil.
[4] IQVIA Institute. (2021). The Role of Indian Pharmaceutical Manufacturing in Global Markets.
